FFA
AZN icon

Freedman Financial Associates’s AstraZeneca AZN Stock Holding History

Freedman Financial Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-367
Closed -$49K – 36
2022
Q1 		$49K Hold
367
– – 0.03% 201
2021
Q4 		$43K Hold
367
– – 0.03% 222
2021
Q3 		$44K Buy
367
+220
+150% +$25.6K 0.03% 209
2021
Q2 		$18K Hold
147
– – 0.01% 298
2021
Q1 		$15K Hold
147
– – 0.01% 321
2020
Q4 		$15K Buy
+147
New +$15.6K 0.01% 322

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Freedman Financial Associates's AZN Position: Q2 2022 in Review

Freedman Financial Associates sold out of AstraZeneca (AZN) in Q2 2022, closing a stake of 367 shares — an estimated $49K sold.

Freedman Financial Associates first reported a position in AZN in Q4 2020 and held it in 6 quarters. The position peaked at $49K in Q1 2022. 1,015 funds tracked by Wall St. Rank hold AZN as of Q2 2022.

  • Freedman Financial Associates reported no remaining AstraZeneca position as of Q2 2022 after selling out during the quarter.
  • Freedman Financial Associates sold 367 AstraZeneca shares in Q2 2022, an estimated $49K.
  • Freedman Financial Associates first reported a position in AstraZeneca in Q4 2020 and held it in 6 quarters.
  • Freedman Financial Associates's AstraZeneca position peaked at $49K in Q1 2022.
  • 1,015 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.

Based on Freedman Financial Associates's 13F filing for Q2 2022.